News

Merck, a leading science and technology company, has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more robust, scalable vaccine manufacturing processes. Merck will provide funding and expertise in the...

Pfizer Inc announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China. This innovative facility will...

Takeda announced that it has dosed the first subject in a Phase 2b field efficacy trial of Takeda’s norovirus vaccine candidate (TAK-214), the only norovirus vaccine candidate in human clinical trials. The Phase 2b, double-blind, randomized,...

The Innovation Days are a unique international event focused on promoting innovation in the field of Life Sciences . For its 7th edition , this event will bring to Paris 600 innovators and health : pharmaceutical companies, startups ,...

Company will pursue an indication for the drug in treatment of Duchenne Muscular Dystrophy.Mallinckrodt plc a leading global specialty biopharmaceutical company, announced it has submitted an Investigational New Drug (IND) application for Synacthen® Depot to the U.S. Food and...

Shire plc announced that the U.S. FDA has granted Breakthrough Therapy Designation for two investigational products for rare diseases: SHP621 (budesonide oral suspension, or BOS) for eosinophilic esophagitis (EoE), and SHP625 (maralixibat) for progressive familial intrahepatic cholestasis type 2...

Pfizer Inc announced the publication of findings from the Phase 3 INO-VATE ALL study in the online issue of The New England Journal of Medicine. The study, also known as Study 1022, is an open-label, randomized,...